Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
 <li>
<a href="https://smartkarma.com/entities/hvivo-plc">hVIVO</a> is the global leader in human challenge trials (HCT), a niche and high-growth segment of the Contract Research Organisation (CRO) market, providing it with a significant competitive advantage.</li>
 <li>The company is strategically diversifying its services beyond HCT to become a full-service early-phase CRO, incorporating clinical trial services, advanced laboratory services (hLAB), and drug development consulting, which is expected to provide more resilient and diversified revenue streams.</li>
 <li>After a challenging 2025 marked by macroeconomic headwinds and contract cancellations, <a href="https://smartkarma.com/entities/hvivo-plc">hVIVO</a> is poised for a return to growth in 2026, supported by a strong order book, expanded capacity, and a broader service offering.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
hVIVO is the global leader in human challenge trials (HCT), a niche and high-growth segment of the Contract Research Organisation (CRO) market, providing it with a significant competitive advantage.
  The company is strategically diversifying its services beyond HCT to become a full-service early-phase CRO, incorporating clinical trial services, advanced laboratory services (hLAB), and drug development consulting, which is expected to provide more resilient and diversified revenue streams.
  After a challenging 2025 marked by macroeconomic headwinds and contract cancellations, hVIVO is poised for a return to growth in 2026, supported by a strong order book, expanded capacity, and a broader service offering.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Research from Hardman & Co, Hardman & Co

Hardman & Co

Research from Hardman & Co

Investment research on quoted companies and funds

Hardman & Co is a multi-disciplinary financial consultancy and investment research firm, employing highly experienced analysts and professionals with a broad range of capital markets expertise. Our clients are public and private businesses as well as fund managers, ranging from start-ups to £1 billion+ market capitalisations. Hardman & Co offers corporate research & consultancy, serving the needs of both public and private companies. We produce gold-standard research with a global reach for trading and investment companies, as well as providing market commentary and analysis. In addition, we carry out a number of bespoke investment-related assignments, including due diligence on bond listings, assessments of private company valuations and other corporate advisory services. We engage with the market through traditional and digital media, offering illuminating video content on corporate management strategy, results communication, interviews and in-house sector discussion.

Thematic (Sector/Industry)

<ul>
<li>The Hardman &amp; Co Healthcare Index (HHI) has been running since 2009.</li>
<li>Its main function is to highlight the attractions of life sciences investments over the long term.</li>
<li>After three years of annual declines, the HHI rebounded 17.6% to 469.1 in 2025.</li>
</ul>


The Hardman &amp; Co Healthcare Index (HHI) has been running since 2009.
Its main function is to highlight the attractions of life sciences investments over the long term.
After three years of annual declines, the HHI rebounded 17.6% to 469.1 in 2025.


Hardman & Co Healthcare Index: 2025 – Index rose, but another tough year

Fundamental Analyses, Contrarian Cashflows

Contrarian Cashflows

Fundamental Analyses

The purpose of Contrarian Cashflows is to document my investment research and share it with everyone who is interested in value investing. My long term aspiration for Contrarian Cashflows is to become a platform for professional investors and serious amateurs where they can get inspiration and discuss investing-related topics.
I plan to publish one company deep dive per month that is guided by my investment approach. All information I use for my write-ups is publicly available and most of the time directly sourced from public filings issued by the respective companies. To guarantee maximum transparency, for every post I provide a list of all used sources in the resources section.
Contrarian Cashflows is built around the principles of respect, honesty, open-mindedness and a touch of humour. Please consider these principles in any engagement interaction with me, other readers and the content on this blog. Misbehaviour is not tolerated.
If you want to reach out to me directly, the best way is via LinkedIn, Twitter or email. You can find the details at my homepage contrariancashflows.com

Each week, I’ll share five intriguing investment ideas that recently caught my attention. These ideas are meant to spark your research and help you kickstart the week ahead with fresh insights.
Because these ideas are the result of my first-level idea generation process, they require more in depth research. Therefore, the ideas will often be concise, with occasional references to valuable work from other practitioners that I encourage you to explore.
If you have something fascinating to share that could benefit me and the wider community, don’t hesitate to send it my way—I’d love to hear from you!

Each week, I’ll share five intriguing investment ideas that recently caught my attention. These ideas are meant to spark your research and help you kickstart the week ahead with fresh insights.
Because these ideas are the result of my first-level idea generation process, they require more in depth research. Therefore, the ideas will often be concise, with occasional references to valuable work from other practitioners that I encourage you to explore.
If you have something fascinating to share that could benefit me and the wider community, don’t hesitate to send it my way—I’d love to hear from you!

<ul>
<li>The Hardman &amp; Co Healthcare Index (HHI) has been running since 2009.</li>
<li>Its main function is to highlight the attractions of life sciences investments over the long term.</li>
<li>For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector.</li>
</ul>


The Hardman &amp; Co Healthcare Index (HHI) has been running since 2009.
Its main function is to highlight the attractions of life sciences investments over the long term.
For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector.


Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences

Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

<ul>
<li>AIREA 27.00p £10.75m (AIEA.L) The UK design-led specialist flooring Company supplying both the UK and international markets announced a trading update for the six months ended 30 June 2026.</li>
<li>Group sales for the Period were 10.2% ahead of the prior year at £10.81m (H1 2025: £9.81m), including volume growth of 7.4%.</li>
<li>Group operating profit for the Period was ahead of the prior year and the Board expects the strong momentum to continue through the remainder of the year and remains confident in the Group's long-term prospects and its ability to deliver sustainable long-term value for shareholders.</li>
</ul>


AIREA 27.00p £10.75m (AIEA.L) The UK design-led specialist flooring Company supplying both the UK and international markets announced a trading update for the six months ended 30 June 2026.
Group sales for the Period were 10.2% ahead of the prior year at £10.81m (H1 2025: £9.81m), including volume growth of 7.4%.
Group operating profit for the Period was ahead of the prior year and the Board expects the strong momentum to continue through the remainder of the year and remains confident in the Group's long-term prospects and its ability to deliver sustainable long-term value for shareholders.


United Kingdom

hVIVO is a full-service early-phase Contract Research Organisation (CRO) and a global leader in human challenge trials. The company provides end-to-end clinical development services, specializing in conducting human challenge trials across various infectious and respiratory indications, and offers comprehensive virology and immunology laboratory services under the hLAB brand. It was founded in 1988 and is headquartered in London, United Kingdom.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

hVIVO (HVO LN)

Primer: hVIVO (HVO LN) - Aug 2026

hVIVO is the global leader in human challenge trials (HCT), a niche and high-growth segment of the Contract Research Organisation (CRO) market,...

αSK Primers

Hardman & Co Healthcare Index: 2025 – Index rose, but another tough year

The Hardman & Co Healthcare Index (HHI) has been running since 2009.Its main function is to highlight the attractions of life sciences investments...

Hardman & Co

Monday Delight: 28/07/25

Each week, I’ll share five intriguing investment ideas that recently caught my attention. These ideas are meant to spark your research and help you...

Contrarian Cashflows

Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments...

Hardman & Co

Hybridan Small Cap Feast: 23 July 2026

The UK design-led specialist flooring Company supplying both the UK and international markets announced a trading update for the six months ended...

Hybridan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)